Stats for this track
More tracks by BMJ talk medicine
Tamiflu (oseltamivir) is a neuraminidase inhibitor, developed by Roche, for the treatment of seasonal and pandemic influenza. Yet for the first time a comprehensive review of the data, by independent researchers, has shown that the claims for Tamiflu’s effectiveness have been overestimated, and that harms have been underreported.
Here is the audio of a recent press conference where researchers and the BMJ's editors describe the findings of that research, and the systematic regulatory failures those findings expose.
Taking part were:
Fiona Godlee - BMJ editor in chief
Carl Heneghan - Director of Oxford University's Centre for Evidence Based Medicine
Peter Doshi - Assistant Professor of Pharmaceutical Health Services Research
Elizabeth Loder - The BMJ clinical epidemiology editor
David Tovey - Editor in chief, Cochrane Library
Ben Goldacre - Founder of the AllTrials campaign